Dhalla Shayesta
University of British Columbia, Vancouver, British Columbia, Canada.
J Med Microbiol. 2015 Jul;64(7):731-738. doi: 10.1099/jmm.0.000073. Epub 2015 Apr 23.
Human immunodeficiency virus (HIV) vaccine preparedness studies (VPSs) have taken place in both the Organisation for Economic Co-operation and Development (OECD) countries and the non-OECD countries. HIV VPSs are conducted to assess the feasibility of phase 3 HIV vaccine trials. This descriptive review is an update of HIV VPSs in the non-OECD countries, and examines the willingness to participate (WTP) in hypothetical HIV vaccine trials, as well as retention. Few VPSs have been published in the OECD countries since the discontinuation of the STEP/Phambili HIV vaccine trials. Barriers to participation in the non-OECD countries after the STEP/Phambili studies include safety issues and side effects, vaccine-induced seropositivity (VISP) and mistrust among key informants (KIs). HIV VPSs indicate that HIV vaccine trials are still feasible in the non-OECD countries, but barriers must be overcome to improve feasibility. Hypothetical WTP in a VPS may not translate into actual WTP in an HIV vaccine trial.
人类免疫缺陷病毒（HIV）疫苗准备研究（VPS）已在经济合作与发展组织（OECD）国家和非经合组织国家开展。进行HIV VPS是为了评估3期HIV疫苗试验的可行性。本描述性综述是对非经合组织国家HIV VPS的更新，研究了在假设的HIV疫苗试验中的参与意愿（WTP）以及保留率。自STEP/Phambili HIV疫苗试验停止以来，经合组织国家很少发表VPS相关内容。STEP/Phambili研究后，非经合组织国家参与的障碍包括安全问题和副作用、疫苗诱导的血清阳性（VISP）以及关键信息提供者（KIs）之间的不信任。HIV VPS表明，HIV疫苗试验在非经合组织国家仍然可行，但必须克服障碍以提高可行性。VPS中假设的WTP可能无法转化为HIV疫苗试验中的实际WTP。
